Case Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases

Edmund K. Bartlett1,2*, Sandra P. D’Angelo3,4, Ciara M. Kelly3,4, Robert H. Siegelbaum5,6, Charles Fisher7, Cristina R. Antonescu8 and Charlotte E. Ariyan1,2

1 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 2 Department of Surgery, Weill Cornell Medical College, New York, NY, United States, 3 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 4 Department of Medicine, Weill Cornell Medical College, New York, NY, United States, 5 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 6 Department of Radiology, Weill Cornell Medical College, New York, NY, United States, 7 Department of Anesthesiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 8 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States

Treatment options for patients with advanced sarcoma remain limited. Promising responses to checkpoint inhibition have been observed, but responses to single-agent PD-1 inhibition are rare. We report on two patients with multiply recurrent myxofibrosarcoma treated with the combination of regionally administered melphalan (via isolated limb infusion) and pembrolizumab. Both patients had recurrent disease after multiple surgical resections and radiation. Analysis of primary tumors demonstrated microsatellite stable tumors with few mutations. After combination treatment, one patient had a significant partial response of 6 months duration, the second patient had a complete response of 2 years duration. Post treatment biopsies demonstrated immune infiltration into the tumor. These promising responses in patients with multiply recurrent myxofibrosarcoma have prompted the development of an investigator-initiated clinical trial to formally study the combination of regional melphalan and pembrolizumab in a systematic fashion (NCT04332874).

Keywords: Sarcoma, Immunotherapy, isolated limb infusion, undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma

BACKGROUND

Prognosis of advanced sarcoma is poor, with a median survival of 10-15 months in the metastatic setting. Standard cytotoxic chemotherapy agents such as doxorubicin, ifosfamide, and dacarbazine result in objective responses in 10-25% of the patients, and complete responses are rare (1). The development of novel and effective therapies is desperately needed.

Immunotherapeutic strategies may be a promising approach to treating advanced sarcoma, but thus far the response rates are only 5-18% in studies of PD1 alone (2, 3). However, certain sarcoma subtypes may have greater response to immunotherapy than others. For example, analysis demonstrated
increased response rated in undifferentiated pleomorphic sarcoma (UPS) group, a common sarcoma subtype, and prompted an expansion cohort that recently reported a 23% response (9/40 UPS patients) (4). A retrospective analysis of sarcoma patients treated with checkpoint inhibition at MD Anderson additionally identified alveolar soft part sarcoma (ASPS) as a histologic type responsive to pembrolizumab (5). As a result, pembrolizumab has recently been incorporated into the NCCN guidelines for treatment of UPS and ASPS (6). Additional combinatorial approaches to overcome the high rate of primary resistance are under investigation, with some promising responses reported (7, 8).

The mechanisms underlying the observed primary resistance to checkpoint inhibition are not well understood. Most sarcomas, however, have low tumor mutational burden and few tumor infiltrating lymphocytes (TILs); both factors known to associate with poor response to checkpoint inhibition (9). Despite this, when present in sarcomas, pretreatment PD-L1 expression and TIL are associated with a better prognosis, suggesting that local immune activation can overcome the low tumor mutational burden (10). Therefore, strategies to enhance inflammation within the tumor, as seen in other tumors such as melanoma, have therapeutic potential in sarcoma.

One strategy to increase immune infiltration into the tumor microenvironment is administration of chemotherapy. Chemotherapy may sensitize tumors to elimination by the immune system by induction of acute inflammation, inhibition of myeloid-derived suppressor cells, increasing the ratio of effector T cells to T-regulatory cells, and/or down-regulating checkpoint pathways via STAT6-mediated signaling (11). Local chemotherapy via isolated limb perfusion has been employed in sarcoma with some efficacy since the 1950s (12). Conceptually, this was developed to deliver high doses of chemotherapy to the tumor while minimizing the systemic toxicity associated with such doses. Previously, our institution completed a phase 2 study combining local chemotherapy with melphalan (via isolated limb infusion, ILI) and checkpoint inhibition (ipilimumab) for patients with melanoma (13). This combination of ILI and checkpoint inhibition resulted in a 1-year progression-free survival of 58% and a 3-month overall response rate of 85%. Of the two patients with metastatic disease in this trial, both developed a durable (at least 2 years) complete response of not only the regional disease but systemic metastases as well. The current study reports on two patients with recurrent myxofibrosarcoma who were treated off-protocol with a combination therapy of pembrolizumab and ILI and have demonstrated promising responses.

Immunohistochemistry was performed on formalin-fixed paraffin-embedded specimens. Stains utilized included CD3 (#ab15580, Leica Biosystems), CD4 (#104R, Cell Marque), CD8 (#960-4460, Ventana), PD-L1 (#13684, Cell Signaling Technology), and CD163 (#760-4437, Ventana). Images are presented at 20x magnification. Individual mutation status, tumor mutational burden, and microsatellite status were assessed via MSK-IMPACT as previously described (14).

**Case 1**

The first patient is a 79 year-old female with a history of 5 prior surgical resections and radiation for a locally recurrent high grade myxofibrosarcoma of the lower extremity. Genomic analysis demonstrated alterations in tumor suppressor genes, including deletions in TP53 (W146fs) and CDKN2A. The tumor was microsatellite stable, with a tumor mutational burden of 3.5 mutations per megabase. She was referred for amputation but opted for an ILI with concurrent pembrolizumab in an attempt to salvage the limb. At presentation she had numerous (at least 12) lesions in the vicinity of her prior operations but no evidence of distant disease (Figure 1A). She received a single dose of pembrolizumab followed by ILI within two weeks and was subsequently maintained on pembrolizumab post-infusion according to the standard dosing schedule. The patient had a partial response of 6 months duration (Figure 1B). All of the lesions that completely regressed continued with a complete response. At 5 months, she developed symptomatic hypothyroidism and pembrolizumab was held. Progression was noted in the lesions that had partially responded before pembrolizumab was resumed.

A biopsy of one of the responding lesions showed a brisk lymphocytic infiltrate (Figures 1C, D). The patient went on to other limb salvage treatment when the remaining lesions grew off treatment. She remains alive with disease now 30 months post-ILI.

**Case 2**

The second patient is a 77 year-old female who had seven prior surgical resections as well as radiation for multiply recurrent high grade myxofibrosarcoma of the lower extremity. She presented one year after her 7th resection with recurrent disease, a 4.1cm x 2.9cm mass overlying the anterior tibia, a possible adjacent soft-tissue tumor nodule, and metastatic disease in an inguinal lymph node (Figure 2A). Genomic analysis revealed a TP53 (R342*) mutation and ATRX deletion. The tumor was microsatellite stable, with a tumor mutational burden of 0.9 mutations per megabase. She received a single dose of pembrolizumab followed by ILI a week later. She subsequently continued on pembrolizumab for one year. Her response to treatment was rapid with resolution of her palpable inguinal node and softening of her tibial lesion at her 1-month follow up. Both the lesion in the chemotherapy infusion field (tibia) and outside the infusion field (inguinal lymph node) demonstrate ongoing radiologic complete response at two years (Figure 2B).

Compared to the pathologic appearance of the excision specimen a year prior (Figure 3A), a tibial biopsy performed
FIGURE 1 | Response in Case 1 treated with ILI and pembrolizumab. (A), Baseline clinical pictures of the numerous recurrent lesions. (B), 6-month follow-up demonstrating significant partial response in the infused limb. (C), CD3+ T cell infiltrate in leg soft-tissue biopsy of a responding lesion. (D), CD8+ T cell infiltrate. Immunohistochemistry images are presented at 20x magnification.

FIGURE 2 | Response in Case 2 treated with ILI and pembrolizumab. (A), Baseline CT scan with lesions noted. (B), 2-year follow-up scan demonstrating ongoing response both in infused limb and at distant site.
one month after ILI revealed >99% treatment effect (Figure 3B). PD-L1 expression was absent in the post-treatment biopsy, with extensive CD4+ and CD8+ T cell infiltrate, as well as CD163+ macrophage infiltrate (Figures 3C–F).

**DISCUSSION**

This report presents two cases demonstrating promising responses to PD-1 checkpoint inhibition when combined with regional chemotherapy in patients with multiply recurrent myxofibrosarcoma. To our knowledge, these are the first two cases of patients with sarcoma treated with this combination therapy. One response was durable for 6 months and the other is ongoing at two years. Responses were observed not only in the limb perfused with melphalan during the ILI, but also (in Case 2) in a regional lymph node which was outside of the field treated with chemotherapy.

Local chemotherapy via ILI alone has been reported to achieve response rates of ~50%, but the widespread adoption of this therapy has been limited by the short duration of response as well as the inability of the local therapy to impact on the development of distant metastases (15). In one large series of patients with sarcoma undergoing local chemotherapy, 40% developed distant recurrence during follow-up, with a median time to distant recurrence of 4.6 months (16). Thus our aim in combining regional chemotherapy with pembrolizumab is not just to enhance local control, but to sensitize these tumors to checkpoint inhibition and thereby potentiate the duration of response as well as treatment of systemic disease.

The highly inflamed tumor microenvironment observed in the post-treatment biopsies by immunohistochemistry in the two presented cases is consistent with the pro-inflammatory effects observed in patients treated with systemic chemotherapy in other tumor types (11, 13). Specifically in melanoma, *in vitro* melphalan treatment of B16 melanoma cells has been found to increase expression of MHC class I and PD-L1 (13). In a B16OVA mouse model of melanoma, the combination of melphalan and checkpoint blockade (anti-CTLA-4) improved survival and resulted in long term anti-tumor immunity in a majority of mice. Tumors treated with both therapies had fewer T-regulatory (Foxp3+) cells and an increased CD8/Treg ratio (13). Furthermore, melphalan exposure *via* isolated limb perfusion is associated with increased IL-1B, IL-6, and IL-8 within patient tumor samples (17). The gene expression pattern after ILI with melphalan demonstrates upregulation of proinflammatory transcripts (TREM1, CCL3, CCL3L1, TNFRSF10C), costimulatory ligands (CD80, CD86, ICOS), and MHC class I and II genes (13). When ILI was followed by checkpoint inhibition (ipilimumab) for patients with melanoma, increased expression of cytotoxic T-cell-effector transcripts (GZMA, GZMH, IFNg, PRF1) was observed (13). Regional delivery of chemotherapy has particular theoretic appeal as a pro-inflammatory therapy. Regional therapy is tolerated at substantially higher doses than systemic therapy, potentially inducing greater inflammation, and the myelosuppressive effects of many systemic agents are avoided when therapy is delivered regionally.

It should be noted that the inflammation induced by limb infusion is not necessarily entirely anti-tumorigenic, M2-polarized macrophages (CD163+) may represent pro-tumorigenic inflammation (18). Macrophage infiltrate is frequently observed across sarcoma histologic types (10). In select subtypes, tumor-associated macrophages do appear to have a pro-tumorigenic role and have even recently been successfully targeted therapeutically in sarcoma models and in
to formally study this combination in patients with sarcoma. Subsequently, we opened a clinical trial of ILI and pembrolizumab as guided by the preclinical data, the results of a similar approach in chemotherapy and checkpoint blockade. However, in light of tumor microenvironment to the combination of local limits the ability to directly attribute the observed inflammatory tumor microenvironment to the combination of local chemotherapy and checkpoint blockade. However, in light of the preclinical data, the results of a similar approach in melanoma, and these two promising responses, we have subsequently opened a clinical trial of ILI and pembrolizumab to formally study this combination in patients with sarcoma (NCT04332874).

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

Study conception and design: SD’A and CEA. Data acquisition: EB, SD’A, CK, RS, CF, CRA, and CEA. Analysis and interpretation of data: EB, SD’A, CK, RS, CF, CRA, and CEA. Drafting or critical revision of manuscript: EB, SD’A, CK, RS, CF, CRA, and CEA. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported in part by Cancer Center Support Grant (NIH/NCI P30 CA08748) and by F50 CA217694 (CRA). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**ACKNOWLEDGMENTS**

The authors would like to thank both patients for their willingness to allow for publication of their cases. The authors acknowledge the support of the Molecular Diagnostics Service in the Department of Pathology, and the Marie-Josee and Henry R. Kravis Center for Molecular Oncology for use of MSK-IMPACT sequencing data.

**REFERENCES**

1. Brennan MF, Antonescu CR, Maki RG. Management of Soft Tissue Sarcoma. Vol. xv. Springer (2013). p. 380.
2. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in Advanced Soft-Tissue Sarcoma and Bone Sarcoma (SARCO28): A Multicentre, Two-Cohort, Single-Arm, Open-Label, Phase 2 Trial. *Lancet Oncol* (2017) 18(11):1493–501. doi: 10.1016/S1470-2045(17)30624-1
3. D’Angelo SP, Mahoney MB, Van Tine BA, Atkins J, Milhem MM, Jalagiraj BN, et al. Nivolumab With or Without Ipilimumab Treatment for Metastatic Sarcoma (Alliance A091401): Two Open-Label, Non-Comperative, Randomised, Phase 2 Trials. *Lancet Oncol* (2018) 19(3):416–26. doi: 10.1016/S1470-2045(18)30006-8
4. Burgess MA, Bolejack V SS, et al. Clinical Activity of Pembrolizumab (P) in Undifferentiated Pleomorphic Sarcoma (UPS) and Dedifferentiated/ Pleomorphic Liposarcoma (LPS): Final Results of SARC028 Expansion Cohorts. *J Clin Oncol* (2019) 37(suppl; abstr 11015). doi: 10.1200/JCO.2019.37.15_s suppl.11015
5. Grosberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, et al. Characteristics and Outcomes of Patients With Advanced Sarcoma Enrolled in Early Phase Immunotherapy Trials. *J Immunother Cancer* (2017) 5(1):100. doi: 10.1186/s40425-017-0301-y
6. Klemen ND, Kelly CM, Bartlett EK. The Emerging Role of Immunotherapy for the Treatment of Sarcoma. *J Surg Oncol* (2021) 123(3):730–8. doi: 10.1002/jso.26306
7. Kelly CM, Antonescu CR, Bowler T, Munhoz R, Chi P, Dickson MA, et al. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. *JAMA Oncol* (2020) 6(3):402–8. doi: 10.1001/jamaoncol.2019.6152
8. Martin-Broto J, Hindi N, Grignani G, Martinez-Trufere J, Redondo A, Valverde C, et al. Nivolumab and Sunitinib Combination in Advanced Soft Tissue Sarcomas: A Multicenter, Single-Arm, Phase Ib/II Trial. *J Immunother Cancer*. (2020) 8(2). doi: 10.1136/jitc-2020-001561
9. Cancer Genome Atlas Research Network and Electronic address edsc, Cancer Genome Atlas Research Network. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. *Cell* (2017) 171(4):950–965 e28. doi: 10.1016/j.cell.2017.10.014
10. D’Angelo SP, Shoushtari AN, Agaram NP, Duk D, Qin LX, Carvajal RD, et al. Prevalence of Tumor-Infiltrating Lymphocytes and PD-L1 Expression in the Soft Tissue Sarcoma Microenvironment. *Hum Pathol* (2015) 46(3):357–65. doi: 10.1016/j.humpath.2014.11.001
11. Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, et al. Effects of Conventional Therapeutic Interventions on the Number and Function of
Regulatory T Cells. *Oncoimmunology* (2013) 2(10):e27025. doi: 10.4161/onci.27025

12. Creech OJr., Krementz ET, Ryan RF, Winblad JN. Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit. *Ann Surg* (1958) 148(4):616–32. doi: 10.1097/00000658-195810000-00009

13. Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, et al. Robust Antitumor Responses Result From Local Chemotherapy and CTLA-4 Blockade. *Cancer Immunol Res* (2018) 6(2):189–200. doi: 10.1158/2326-6066.CIR-17-0356

14. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. *J Mol Diagn* (2015) 17(3):251–64. doi: 10.1016/j.jmoldx.2014.12.006

15. Mullinax JE, Kroon HM, Thompson JF, Nath N, Mosca PJ, Farma JM, et al. Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma. *J Am Coll Surg* (2017) 224(4):635–42. doi: 10.1016/j.jamcollsurg.2016.12.035

16. Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM. Outcome and Prognostic Factor Analysis of 217 Consecutive Isolated Limb Perfusion With Tumor Necrosis Factor-Alpha and Melphalan for Limb-Threatening Soft Tissue Sarcoma. *Cancer* (2006) 106(8):1776–84. doi: 10.1002/cncr.21802

17. Dudek-Peric AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S, et al. Antitumor Immunity Triggered by Melphalan Is Potentiated by Melanoma Cell Surface-Associated Calreticulin. *Cancer Res* (2015) 75(8):1603–14. doi: 10.1158/0008-5472.CAN-14-2089

18. Channan T, Ontong P, Konno K, Itano N. Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment. *Cancers (Basel)* (2014) 6(3):1670–90. doi: 10.3390/cancers6031670

19. Fujiwara T, Yakouk MA, Chandler A, Christ AB, Yang G, Ouerfelli O, et al. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-Cell Infiltration in the Sarcoma Microenvironment. *Mol Cancer Ther* (2021) 20(8):1388–99. doi: 10.1158/1535-7163.MCT-20-0591

20. Tap WD, Gelderblom H, Palmieri E, Desai J, Bauer S, Blay JY, et al. Pexidartinib Versus Placebo for Advanced Tenosynovial Giant Cell Tumour (ENLIVEN): A Randomised Phase 3 Trial. *Lancet* (2019) 394(10197):478–87. doi: 10.1016/S0140-6736(19)30764-0

**Conflict of Interest:** CK reports receiving research funding from Merck, Amgen, and Agios; SD’A reports research funding from Amgen, EMD Serono, Incyte, Merck & Co., Nektar, Bristol-Myers Squibb, and Deciphera; consultancy for Amgen, EMD Serono, GlaxoSmithKline, Immune Design, Incyte, Merck & Co., Nektar, and Immunocore; reimbursement for travel expenses from EMD Serono, Merck & Co., Adaptimmune, and Immunocore.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Bartlett, D’Angelo, Kelly, Siegelbaum, Fisher, Antonescu and Ariyan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.